H pylori Treatment and Gastric Cancer Risk Among Patients With High Genetic Risk

Heng-Min Xu,Yuting Han,Zong-Chao Liu,Zhou-Yi Yin,Meng-Yuan Wang,Canqing Yu,Jun-Ling Ma,Dianjianyi Sun,Wei-Dong Liu,Yang Zhang,Tong Zhou,Jing-Ying Zhang,Pei Pei,Ling Yang,Iona Y. Millwood,Robin G. Walters,Yiping Chen,Huaidong Du,Zhengming Chen,Wei-Cheng You,Liming Li,Kai-Feng Pan,Jun Lv,Wen-Qing Li
DOI: https://doi.org/10.1001/jamanetworkopen.2024.13708
2024-05-30
JAMA Network Open
Abstract:This cohort study examines whether outcomes of primary prevention strategies for gastric cancer, including Helicobacter pylori treatment, differ by genetic risk profile among adults in China.
medicine, general & internal
What problem does this paper attempt to address?
This paper aims to explore the impact of genetic susceptibility on the outcomes of primary prevention strategies for gastric cancer (GC). Specifically, researchers constructed a polygenic risk score (PRS) by analyzing data from a large number of Chinese adults to assess its correlation with gastric cancer risk. They further investigated whether *Helicobacter pylori* (Hp) treatment and nutritional supplementation could effectively reduce the risk of gastric cancer in individuals with high genetic risk. The study found that Hp treatment significantly reduced the risk of gastric cancer in individuals with high genetic risk, while this effect was not observed in individuals with low genetic risk. This suggests that Hp treatment may be an effective primary prevention measure for gastric cancer in populations with high genetic risk. Additionally, the study found no significant differences in the effects of vitamin or garlic supplements between different genetic risk groups. Therefore, the results support the effectiveness of Hp treatment for individuals with high genetic risk and suggest that genetic susceptibility should be considered when formulating effective primary prevention strategies for gastric cancer.